



S.S.H.medical Limited

8 April 2004

The Company Announcements Office
Australian Stock Exchange
Level 6, 20 Bridge Street
Sydney
NSW 2000

FOR RELEASE TO THE MARKET

Dear Sirs

Please find enclosed an announcement from SSH Medical Limited for release to the market.

Yours faithfully

D W Ward
Chief Financial Officer.



S.S.H.medical Limited

8 April 2004

SSH Announces TGA listing of Workstation by Therapeutic Goods Administration

SSH is pleased to advise that the Company has received notification from the Therapeutic Goods Administration that the multi-function WS-XII Workstation is to be listed in the Australian Register of Therapeutic Goods.

TGA Listing-

The company had previously advised that it had received EMC certification by Testing and Certification Australia. TGA listing of the product was the last regulatory hurdle in the commercialisation path for the Workstation.

This significant milestone marks the completion of the development phase of this ground breaking product.

WS-XII Workstation Product

The Workstation product incorporates a number of significant advantages of benefit to the medical profession and General Practitioners in particular. It incorporates into one single multi-purpose unit twelve essential functions including a number that have not previously been readily available to General Practitioners. The system incorporates two miniaturised cameras enabling practitioners to capture and retain images as a digital witness of the procedure and subsequent retrieval of the image will enable comparison with then current images.

Test data is processed through a network enabled personal computer (integrated into the Workstation) for display through a 15" LCD monitor and/or stored within the practitioner's clinical records database for future use and reference.

The product created considerable interest among practitioners when an advanced prototype was previewed at the 2003 GPCPE General Practitioner Conference. Since then considerable effort has been directed at refining the product as part of its development path.

Following receipt of this TGA approval, the company will release a limited number of units for trial and assessment by selected practitioners as part of the shake down trials in the lead up to the commercialisation of the product.

For more information in relation to SSH or its products visit our website www.sshmedical.com

John E Dunn
Managing Director / CEO